drugset / Trial / NCT06676423

Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

NCT06676423

Phase 1 Completed 8 enrolled Corestemchemon, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial is a single-center, open-label, and phase I clinical trial to Evaluate the Safety of Neuronata-R® Inj. suspended with HypoTHermosol® FRS (HTS-FRS) in Patients with Amyotrophic Lateral Sclerosis.

Timeline

Start
2022-11-09
Primary completion
2023-11-27
Completion
2023-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenzumestrocel Cell therapy 1e+06 cells/kg Intrathecal
Background Riluzole Small molecule